Stiefel (nine products) Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Stiefel (nine products) General Information

Description

Stiefel, a GlaxoSmithKline company, sold off nine dermatology products to Renaissance Pharma. Renaissance Pharma was given the rights to manufacture, market and sell all nine products. These products from GSK and Stiefel, which will be marketed through Renaissance's branded division Prestium Pharma ("Prestium"), include: 1. Evoclin® (clindamycin phosphate) Foam, 1% 2. Extina® (ketoconazole) Foam, 2% 3. Luxiq® (betamethasone valerate) Foam, 0.12% 4. Olux® (clobetasol propionate) Foam, 0.05% 5. Olux-E® (clobetasol propionate) Foam, 0.05% 6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment 7. Zovirax® (acyclovir) Capsules 8. Zovirax® (acyclovir) Tablets 9. Zovirax® (acyclovir) Suspension

Contact Information

Website
www.stiefel.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 20 T.W. Alexander Drive
  • Durham, NC 27709
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Personal Products
Vertical(s)
Corporate Office
  • 20 T.W. Alexander Drive
  • Durham, NC 27709
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Stiefel (nine products) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Stiefel (nine products)‘s full profile, request access.

Request a free trial

Stiefel (nine products) Patents

Stiefel (nine products) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160081895-A1 Novel formulations Inactive 18-Sep-2014
WO-2014182655-A1 Assay for screening a compound for the ability to modulate proinflammatory cytokine production in human skin Inactive 06-May-2013
AU-2014218800-A1 Non-aqueous solid stabilized emulsions Active 22-Feb-2013
AU-2014218800-B2 Non-aqueous solid stabilized emulsions Inactive 22-Feb-2013
AU-2014218800-C1 Non-aqueous solid stabilized emulsions Inactive 22-Feb-2013 A61K8/0241
To view Stiefel (nine products)’s complete patent history, request access »

Stiefel (nine products) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Stiefel (nine products)‘s full profile, request access.

Request a free trial

Stiefel (nine products) FAQs

  • When was Stiefel (nine products) founded?

    Stiefel (nine products) was founded in 2001.

  • Where is Stiefel (nine products) headquartered?

    Stiefel (nine products) is headquartered in Durham, NC.

  • What industry is Stiefel (nine products) in?

    Stiefel (nine products)’s primary industry is Pharmaceuticals.

  • Is Stiefel (nine products) a private or public company?

    Stiefel (nine products) is a Private company.

  • What is Stiefel (nine products)’s current revenue?

    The current revenue for Stiefel (nine products) is .

  • Who are Stiefel (nine products)’s investors?

    GSK has invested in Stiefel (nine products).

  • When was Stiefel (nine products) acquired?

    Stiefel (nine products) was acquired on 01-May-2013.

  • Who acquired Stiefel (nine products)?

    Stiefel (nine products) was acquired by Renaissance Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process